Literature DB >> 10960046

Nitric oxide-induced headache in patients with chronic tension-type headache.

M Ashina1, L Bendtsen, R Jensen, J Olesen.   

Abstract

An experimental model of headache offers unique possibilities to study the mechanisms responsible for head pain. Using the glyceryl trinitrate [GTN; nitric oxide (NO) donor] model of experimental headache, we studied the intensity, quality and time profile of headache after infusion of GTN in 16 patients with chronic tension-type headache and in 16 healthy controls. Subjects were randomized to receive intravenous infusion of GTN (0.5 microg/kg per minute for 20 min) or placebo on two headache-free days separated by at least 1 week. Headache intensity was measured on a 10-point verbal rating scale during 2 h of observation and for the next 10 h after discharge from hospital. The primary endpoints were the difference between the area under the curve (AUC-intensities x duration) for headache recorded on the day of GTN treatment and on the day of placebo treatment in patients, and in patients and controls on the days of GTN treatment. In patients, the AUC on a GTN day [2221 (1572-3704); median with quartiles in parentheses], was significantly greater than on a placebo day [730 (60-1678), P: = 0. 008]. On the GTN day, the AUC in patients [2221 (1572-3704)] was significantly higher than in controls [43 (0-972), P: = 0.0001]. In patients, peak pain intensity occurred 8 h after infusion of GTN, whereas in controls it occurred 20 min after the start of infusion. The present study demonstrates that an NO-induced biphasic response with an immediate and a delayed headache is common to chronic tension-type headache and migraine. Furthermore, the NO-induced delayed headache has the characteristics of the primary headache disorder. This suggests that NO contributes to the mechanisms of several types of primary headaches and that NO-related central sensitization may be an important common denominator in the pain mechanisms of primary headaches.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960046     DOI: 10.1093/brain/123.9.1830

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  22 in total

Review 1.  Central and peripheral sensitization in tension-type headache.

Authors:  Lars Bendtsen
Journal:  Curr Pain Headache Rep       Date:  2003-12

Review 2.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 3.  Diagnostic issues in tension-type headache.

Authors:  Sara Sacco
Journal:  Curr Pain Headache Rep       Date:  2008-12

Review 4.  The role of muscles in tension-type headache.

Authors:  Lars Bendtsen; César Fernández-de-la-Peñas
Journal:  Curr Pain Headache Rep       Date:  2011-12

Review 5.  Nitric oxide-related drug targets in headache.

Authors:  Jes Olesen
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 6.  Tension type headache in adolescence and childhood: where are we now?

Authors:  Teshamae S Monteith; Till Sprenger
Journal:  Curr Pain Headache Rep       Date:  2010-12

7.  Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period.

Authors:  Ravi Gupta; Tanzeel Ahmed; Basudeb Banerjee; Manjeet Bhatia
Journal:  J Headache Pain       Date:  2009-03-11       Impact factor: 7.277

Review 8.  Central mechanisms in tension-type headaches.

Authors:  M Vandenheede; Jean Schoenen
Journal:  Curr Pain Headache Rep       Date:  2002-10

Review 9.  Tension-type headache.

Authors:  Ninan T Mathew
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081

10.  Different Pain States of Trigeminal Neuralgia Make Significant Changes in the Plasma Proteome and Some Biochemical Parameters: a Preliminary Cohort Study.

Authors:  Asghar Farajzadeh; S Zahra Bathaie; Jalil Arabkheradmand; Seyed Mohammad Ghodsi; Soghrat Faghihzadeh
Journal:  J Mol Neurosci       Date:  2018-10-17       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.